Germany - Medicines - Discount agreement under Section 130c (1) SGB V in conjunction with Section 130a (8) SGB V for the active ingredient Erenumab

01

AOK Baden-Württemberg awarded a discount agreement for patent-protected medicines with the active ingredient Erenumab (AIMOVIG). The agreement, concluded under Section 130c (1) SGB V in conjunction with Section 130a (8) SGB V, provides for rebates on this prescription medicine. The contract was won by Novartis Pharma GmbH. An exact contract value cannot be determined because it depends on various unknown factors, so the stated value is only a fictitious figure based on the currently applicable thresholds. No contract duration, number of bids or market re-entry date is given in the notice.

02

Description

03

10 open tenders right now

• Health and safety consultancy - Framework contract for occupational safety and health protection support 14 Oct 2026 · 13 days left
• Cleaning and hygiene services - Rental service contract for dirt control mats for AOK Baden-Wuerttemberg - Lot 2 South/East region 19 Oct 2026 · 18 days left
• Cleaning and hygiene services - Rental service contract for dirt control mats for AOK Baden-Wuerttemberg - Lot 1 North/East area 19 Oct 2026 · 18 days left

Recent awards

• Arzneimittel - Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V i. V. m § 130a Abs. 8 SGB V zum Wirkstoff Crovalimab

  awarded to Roche Pharma AG

• Arzneimittel - Arzneimittelrabattvereinbarung gemäß § 130c Abs. 1 SGB V i. V. m § 130a Abs. 8 SGB V zum Wirkstoff Ravulizumab

  awarded to Alexion Pharma Germany GmbH

• Arzneimittel - Vereinbarung gemäß § 130c Abs. 1 SGB V über die Gewährung von Rabatten für patentgeschützte Arzneimittel mit dem Wirkstoff Eftrenonacog alfa (Alprolix®)

  awarded to Swedish Orphan Biovitrum GmbH

05

Market context

Avg. open tender · Medical equipment & pharmaceuticals

€11,447,367

10,065 open across Europe right now

Buyer track record on Aperlena

55 notices tracked · 36 awarded